Insider Selling: Personalis (NASDAQ:PSNL) CEO Sells $1,508,000.00 in Stock

Personalis, Inc. (NASDAQ:PSNL) CEO Christopher Hall sold 100,000 shares of the stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $15.08, for a total value of $1,508,000.00. Following the transaction, the chief executive officer owned 235,986 shares in the company, valued at $3,558,668.88. This represents a 29.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Personalis Stock Up 3.8%

Shares of Personalis stock traded up $0.54 on Thursday, reaching $14.65. The company’s stock had a trading volume of 5,465,304 shares, compared to its average volume of 3,502,774. The company has a market capitalization of $1.53 billion, a P/E ratio of -14.36 and a beta of 2.24. The stock has a 50-day moving average price of $9.81 and a 200-day moving average price of $8.62. Personalis, Inc. has a 52-week low of $3.84 and a 52-week high of $15.36.

Personalis (NASDAQ:PSNL) last announced its earnings results on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. The firm had revenue of $15.47 million for the quarter, compared to analyst estimates of $14.48 million. Sell-side analysts forecast that Personalis, Inc. will post -1.06 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Personalis

A number of hedge funds have recently added to or reduced their stakes in PSNL. T. Rowe Price Investment Management Inc. raised its holdings in Personalis by 273.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock worth $85,812,000 after purchasing an additional 7,896,714 shares in the last quarter. Aberdeen Group plc raised its stake in Personalis by 36.1% during the 4th quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock worth $25,869,000 after acquiring an additional 861,948 shares in the last quarter. Kennedy Capital Management LLC lifted its position in Personalis by 196.2% in the third quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock valued at $12,617,000 after acquiring an additional 1,281,695 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Personalis by 1,332.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,448,585 shares of the company’s stock valued at $11,531,000 after acquiring an additional 1,347,439 shares during the last quarter. Finally, Millennium Management LLC boosted its stake in Personalis by 11.0% in the third quarter. Millennium Management LLC now owns 1,210,754 shares of the company’s stock valued at $7,894,000 after acquiring an additional 120,027 shares in the last quarter. 61.91% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Wall Street Zen downgraded Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Morgan Stanley boosted their price objective on shares of Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. Finally, BTIG Research reduced their price target on shares of Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $11.67.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.